Hue Lam

Company: Affini-T Therapeutics

Job title: Vice President of Preclinical Development

Seminars:

Developing TCR-Engineered T Cell Therapies Targeting Mutated KRAS 2:30 pm

Showcasing how Affini-T Therapeutics’ TCR discovery platform has identified a library of TCRs with high functional avidity, including those targeting KRAS G12V and G12D Understanding how through the application of gene editing and synthetic biology, engineered TCR-T cells can be enhanced with improved fitness and durability to overcome the immunosuppressive tumor microenvironment. Presenting how with…Read more

day: Day One Track B PM